DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20170561

Efficacy of anti-thrombotic treatment in thrombophilia patients with adverse pregnancy outcome

Anil Kumar Adhikari, Mahuya Dutta, Sk Samim Ferdows, Madhu Jain, Jyoti Shukla

Abstract


Background: Thrombophilia is a potentially treatable cause of adverse pregnancy outcome. The objective was to compare the fetomaternal outcome in thrombophilia patients with adverse pregnancy outcome after treating with low-molecular-weight (LMW)/ unfractionated heparin and aspirin.

Methods: 54 antenatal women studied who had an earlier or presenting pregnancy complicated by adverse pregnancy outcome were included in this study. In the present pregnancy, therapy consisting of LMW heparin and aspirin was administered who were found to be thrombophilia positive. Patients also received folic acid supplementation throughout their pregnancy. The fetomaternal outcome is compared according to the time of initiation of treatment.

Results: Low-molecular-weight heparin and aspirin was well tolerated and none of the women or the newborns developed any hemorrhagic complications.3 thrombophilia negative cases with history of recurrent pregnancy loss aborted even getting treatment from 1 trimester. 1 thrombophilia positive case with history of recurrent pregnancy loss aborted when received treatment from 2nd trimester. There is 25.8% increase in birth weight of neonate if thrombophilia positive cases were treated from 1st trimester. Whereas there was only 10.23% increase in birth weight in thrombophilia negative cases when treated from first trimester. We found, our treatment was significantly effective in preventing IUD, IUGR, abruption, abortion, eclampsia. Though prevention of PIH had no significant correlation with antithrombotic treatment, only 2 cases booked from 1st trimester developed PIH among thrombophilia positive cases. But neither of cases had suffered from any severe complication as compared to 81% of eclampsia cases, 16.67% of DVT cases, 1 case of mortality in cases treated after third trimester.

Conclusions: This case control trial suggests that patients with adverse pregnancy outcome and thrombophilia may get benefit from treatment with combined LMW heparin and aspirin in subsequent pregnancies. We suggest all patients with adverse pregnancy outcome should be investigated for thrombophilia markers.

Keywords


Adverse pregnancy outcome, Anti-thrombotic treatment, Aspirin, LMW heparin, Thrombophilia, Unfractionated heparin

Full Text:

PDF

References


Kupferminc MJ. Thrombophilia and pregnancy. Reprod Biol Endocrinol. 2003;1:11.

Bates SM, Ginsberg JS. How we manage venous thromboembolism during pregnancy. Blood. 2002;100(10):3470-8.

Bates S, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy. Chest. 2004;126:627S-44S.

Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol. 2002;100: 408-13.

Gris JC, Mercier E, Quéré I, Lavigne-Lissalde G, Cochery-Novellon E, Hoffet M, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood. 2004;103:3695-9.

Paidas M, Ku DH, Triche E, Lockwood C, Arkel Y. Does heparin therapy improve pregnancy outcome in patients with thrombophilia? J Thromb Haemost. 2004;2:1194-5.

Duley L, Henderson-Smart D, Knight M, King J. Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. BMJ. 2001;322(7282):329-33.

Leduc L, Dubois E, Takser L, Rey E, David M, Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. J Obstet Gynecol Can. 2007;29(10):787-93.

Ellison J, Walker ID, Greer IA. Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy. BJOG. 2000;107:1116-21.

Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost. 2000;83: 693-7.

Henderson JT, Whitlock EP, O'Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive services task force. Ann Intern Med. 2014;160:695-703.

LeFevre ML. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive services task force recommendation statement. U.S. Preventive services task force. Ann Intern Med. 2014;161:819-26.

Michael K, Eli R, Ariel M, Sharon M, Lessing JB, Gamzu R. Low molecular weight heparin versus no treatment in women with previous severe pregnancy complications and placental findings without thrombophilia. Blood Coagulation and Fibrinolysis. 2011;22(2):123-6.

Kaandorp SP, Goddijn M, van der Post JAM, Hutten BA, Verhoeve HR, Hamulyák K, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010;362:1586-96

Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997;314(7076):253-7.

de Vries JI, van Pampus MG, Hague WM, Bezemer PD, Joosten JH; FRUIT investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemost. 2012;10(1):64-72.

Horlocker TS, Wedel DJ, Rowlingson JC, Enneking FK, Kopp SL, Benzon HT, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American society of regional anesthesia and pain medicine evidence-based guidelines (third edition). Regional Anesthesia and Pain Medicine. 2010;35(1):64-101.

Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost. 2003;1:433-8.

Brenner B, Hoffman R, Carp H, Dulitsky M, Younis J; LIVE-ENOX investigators. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost. 2005;3:227-9.

Kupferminc MJ, Fait G, Many A, Lessing JB, Yair D, Bar-Am A, et al. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy. 2001;20:35-44.

Riyazi N, Leeda M, de Vries JI, Huijgens PC, van Geijn HP, Dekker GA. Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Eur J Obstet Gynecol Reprod Biol. 1998;80:49-54.